How do you approach prophylaxis against glucocorticoid-induced osteoporosis in patients with end-stage renal disease on dialysis?
Answer from: at Academic Institution
Treating patients with end-stage renal disease on glucocorticoids to prevent bone loss is a challenge. A patient with end-stage renal disease cannot be treated with bisphosphonates. However, denosumab the RANKL antibody has no restrictions regarding renal disease. So my suggestion is to treat a pati...
Comments
at Atlantic Health Rheumatology Is there a limit on the length of time that we cou...
at UC Davis Interestingly, there is no limit to the length of ...
at Norton Rheumatology Specialists The package insert for denosumab states that it sh...
at Tristate Arthritis & Rheumatology What anti-resorptive therapy would be recommended ...
at PIH Health How do you differentiate this population of ESRD p...
Is there a limit on the length of time that we cou...
Interestingly, there is no limit to the length of ...
The package insert for denosumab states that it sh...
What anti-resorptive therapy would be recommended ...
How do you differentiate this population of ESRD p...